Evidence map›Paper›PMID 26905203›Full record

ArticleStem cell reports2016

GATA Factor-G-Protein-Coupled Receptor Circuit Suppresses Hematopoiesis.

Xin Gao, Tongyu Wu, Kirby D Johnson, Jamie L Lahvic, Erik A Ranheim, Leonard I Zon, Emery H Bresnick

Open access · goldAbstract read
In one paragraph

Article in Stem cell reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Gpr171 regulates embryonic hematopoietic stem cell emergence via ERK1/2 and Notch signaling.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Xin GaoUW-Madison Blood Research Program, Department of Cell and Regenerative Biology, Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA.
Tongyu WuUW-Madison Blood Research Program, Department of Cell and Regenerative Biology, Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA.
Kirby D JohnsonUW-Madison Blood Research Program, Department of Cell and Regenerative Biology, Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA.
Jamie L LahvicStem Cell Program and Division of Hematology/Oncology, Children's Hospital and Dana Farber Cancer Institute, Howard Hughes Medical Institute, Harvard Medical School, Harvard Stem Cell Institute, Stem Cell and Regenerative Biology Department, Harvard University, Boston, MA 02114, USA.
Erik A RanheimDepartment of Pathology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA.
Leonard I ZonStem Cell Program and Division of Hematology/Oncology, Children's Hospital and Dana Farber Cancer Institute, Howard Hughes Medical Institute, Harvard Medical School, Harvard Stem Cell Institute, Stem Cell and Regenerative Biology Department, Harvard University, Boston, MA 02114, USA.
Emery H BresnickUW-Madison Blood Research Program, Department of Cell and Regenerative Biology, Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA. Electronic address: ehbresni@wisc.edu.
University of Wisconsin–Madison · USUniversity of Wisconsin Carbone Cancer Center · USDana-Farber Cancer Institute · USHarvard Stem Cell Institute · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI AMY TRENTHAM-DIETZ · 1985 to 2026
$142.6M
TRANSCRIPTION FACTOR GATA-1 IN TERMINAL ERYTHROID DEVELOPMENTP01HL032262 · NHLBI · CHILDREN'S HOSPITAL BOSTON · PI ORKIN, STUART H · 1985 to 2021
$38.9M
Customized stem cells for clinical application in blood disordersR24DK092760 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI COLLINS, JAMES J, DALEY, GEORGE Q · 2011 to 2018
$10.7M
Hematopoietic Regulation via GATA SwitchesR01DK068634 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI Emery H. Bresnick · 2006 to 2026
$7.5M
Transcriptional Control of Hemoglobin Synthesis and Erythrocyte DevelopmentR01DK050107 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI Emery H. Bresnick · 1996 to 2026
$6.1M
Project-002U54DK110805 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI ORKIN, STUART H, ZON, LEONARD IRA · 2016 to 2020
$5.9M
EMBRYONIC HEMATOPOIESISR01HL048801 · NHLBI · CHILDREN'S HOSPITAL BOSTON · PI ZON, LEONARD IRA · 1992 to 2016
$5.7M
Transcriptional Control of Hemoglobin SynthesisR37DK050107 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI BRESNICK, EMERY H · 2011 to 2020
$3.5M
Hematopoietic Regulation Via GATA SwitchesR56DK068634 · NIDDK · UNIVERSITY OF WISCONSIN MADISON · PI BRESNICK, EMERY H. · 2005 to 2005
$109k
11,12-Epoxyeicosatrienoic acid regulation of hematopoietic stem cell engraftmentF31HL129517 · NHLBI · HARVARD MEDICAL SCHOOL · PI LAHVIC, JAMIE LEE · 2015 to 2016
$57k
IN VIVO GENE TRANSFER TO PROLIFERATING VASCULAR TISSUEZ01HL004880 · NHLBI · HEART, LUNG, AND BLOOD INSTITUTE · PI FLUGELMAN, M Y · 1991 to 1991
–
Howard Hughes Medical InstituteNCI NIH HHS P30 CA014520NCI NIH HHS P30CA014520NHLBI NIH HHS F31 HL129517NHLBI NIH HHS HL032262NHLBI NIH HHS HL10001-05NHLBI NIH HHS NIH HL04880NHLBI NIH HHS P01 HL032262NHLBI NIH HHS R01 HL048801NIDDK NIH HHS DK092760NIDDK NIH HHS DK50107NIDDK NIH HHS R01 DK050107NIDDK NIH HHS R01 DK068634NIDDK NIH HHS R24 DK092760NIDDK NIH HHS R37 DK050107NIDDK NIH HHS R56 DK068634NIDDK NIH HHS U54 DK110805PHS HHS NIHDK68634
6 · The paper itself

Abstract

Hematopoietic stem cells (HSCs) originate from hemogenic endothelium within the aorta-gonad-mesonephros (AGM) region of the mammalian embryo. The relationship between genetic circuits controlling stem cell genesis and multi-potency is not understood. A Gata2 cis element (+9.5) enhances Gata2 expression in the AGM and induces the endothelial to HSC transition. We demonstrated that GATA-2 rescued hematopoiesis in +9.5(-/-) AGMs. As G-protein-coupled receptors (GPCRs) are the most common targets for FDA-approved drugs, we analyzed the GPCR gene ensemble to identify GATA-2-regulated GPCRs. Of the 20 GATA-2-activated GPCR genes, four were GATA-1-activated, and only Gpr65 expression resembled Gata2. Contrasting with the paradigm in which GATA-2-activated genes promote hematopoietic stem and progenitor cell genesis/function, our mouse and zebrafish studies indicated that GPR65 suppressed hematopoiesis. GPR65 established repressive chromatin at the +9.5 site, restricted occupancy by the activator Scl/TAL1, and repressed Gata2 transcription. Thus, a Gata2 cis element creates a GATA-2-GPCR circuit that limits positive regulators that promote hematopoiesis.

Indexed as

HematopoiesisAnimalsCells, CulturedChromatinGATA2 Transcription FactorHematopoietic Stem CellsMiceReceptors, G-Protein-CoupledZebrafishChromatinGATA2 Transcription FactorReceptors, G-Protein-Coupled

Identifiers

PMID26905203
PMCPMC4788764
OpenAlexW2285943204

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.